(1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-12-{1-[(1R,3R,4R)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl}-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone

• ChemBase编号: 130460
• 分子式: C43H68ClNO11
• 平均质量: 810.45312
• 单一同位素质量: 809.44808968
• SMILES: Cl[C@@H]1CC[C@H](C[C@H]1OC)/C=C(\C)/[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@H](C[C@@H](C)C/C(=C/[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)/C)OC)[C@@H](OC)C[C@H]2C
• Canonical SMILES: CC[C@@H]1/C=C(\C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@@H](C[C@@H]2OC)C)C(=O)C(=O)N2[C@H](C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]1CC[C@H]([C@@H](C1)OC)Cl)/C)CCCC2
• InChI: InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/t25-,27+,28+,29-,30+,31+,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
• InChIKey: KASDHRXLYQOAKZ-HLSLRQMJSA-N

名称和登记号

名称

• IUPAC标准名: (1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-12-{1-[(1R,3R,4R)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl}-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^4,^9]octacos-18-ene-2,3,10,16-tetrone
• IUPAC传统名: (1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-12-{1-[(1R,3R,4R)-4-chloro-3-methoxycyclohexyl]prop-1-en-2-yl}-17-ethyl-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0^4,^9]octacos-18-ene-2,3,10,16-tetrone
• 商标名: Elidel
• 别名: Pimecrolimus

登记号

• CAS号: 137071-32-0
• PubChem SID: 162224739
• PubChem CID: 16051947
• ATC码: D11AH02
• CHEMBL: 1200686
• Chemspider ID: 10482089
• DrugBank ID: DB00337
• 美国药典/FDA物质标识码: 7KYV510875
• 维基百科标题: Pimecrolimus

理论计算性质

• Acid pKa: 9.955626
• 质子受体: 10
• 质子供体: 2
• LogD (pH = 5.5): 6.808116
• LogD (pH = 7.4): 6.806926
• Log P: 6.808131
• 摩尔折射率: 214.0262 cm^3
• 极化性: 84.57097 Å^3
• 极化表面积: 158.13 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: false

分子性质

药理学性质

• 给药途径: topical
• 生物利用度: low systemic absorption
• 代谢: Hepatic CYP3A
• 蛋白结合率: 74%–87%
• 法定药品分级: Rx-only (US)
• 妊娠期药物分类: C (US)